A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients

Launched by BEIJING DITAN HOSPITAL · Dec 20, 2022

Keywords

ClinConnect Summary

During this study, participants will receive HH-120 nasal spray treatment for 6 consecutive days, the efficacy and safety of HH-120 will be assessed throughout the study period based on viral clearance, clinical recovery, illness severity and adverse events.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 to 65 years old.
• • Participants with mild COVID-19 with symptom onset≤5 days or asymptomatic COVID-19.
• • Participants being able and willing to provide informed consent prior to any study-specific procedure.
• Exclusion Criteria:
• • Participants with moderate or severe COVID-19.
• • Participants within the pregnancy or breastfeeding period or plan to be pregnant during the study period.
• • Participants requiring oxygen treatment (such as non-invasive ventilation, invasive mechanical ventilation, ECMO, etc.).
• • Participants with nasal disease that is inconvenient or intolerant of nasal spray administration, or cannot use the nasal spray treatment.
• • Participants with comorbid Malignancy or with a history of malignancy.
• • Participants with active or uncontrolled systemic autoimmune disease.
• • Insufficient function of key organs.
• • Other reasons considered by the investigator to be unsuitable for the trial.